Biologic Therapies in Moderate to Severe Atopic Dermatitis

CE / CME

The Impact of Emerging Biologic Therapies on Managing Moderate to Severe Atopic Dermatitis

Physician Assistants/Physician Associates: 0.25 AAPA Category 1 CME credit

Nurse Practitioners: 0.25 Nursing contact hours, includes 0.25 hour of pharmacotherapy credit

Released: September 25, 2024

Expiration: September 24, 2025

Jonathan Silverberg
Jonathan Silverberg, MD, PhD, MPH

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Which of the following agents has demonstrated efficacy for lesion resolution in moderate to severe AD, but only when combined with a topical corticosteroid or a topical calcineurin inhibitor?